U.S., May 8 -- ClinicalTrials.gov registry received information related to the study (NCT06960928) titled 'Low Dose Sirolimus in People With Post-Acute Sequelae of COVID-19 (PASC) Long COVID-19' on April 29.
Brief Summary: The study is conducted in New York, New York at The Cohen Center for Recovery from Complex Chronic Illness at Mount Sinai.
This is an IND-exempt, off-label, multi-ascending, randomized, placebo-controlled clinical trial of sirolimus (also known as rapamycin) in adults with Long COVID. There are 2 arms: Sirolimus and Placebo.
This study aims to evaluate the efficacy of Sirolimus in adults with Long COVID. Efficacy will be evaluated by measuring patient-reported outcomes in response to Sirolimus.
Study Start Date: May, ...